Cognition Therapeutics Inc SEC filings CGTX

Cognition Therapeutics Inc has 303 filings in SEC EDGAR's recent list, going back to Jan 29, 2009. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations, listing notice). The company's fiscal year ends on December 31.

Cognition Therapeutics Inc SEC filings
Form Description Filed Period
10-Q Quarterly report Nov 5, 2026 Sep 30, 2026
8-K Current report
Results of operations, Listing notice
Nov 5, 2026 Nov 3, 2026
8-K Current report
Other events
Oct 22, 2026 Oct 22, 2026
10-Q Quarterly report Aug 7, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 6, 2026 Aug 6, 2026
8-K Current report
Other events
Jun 24, 2026 Jun 24, 2026
8-K Current report
Shareholder vote results
Jun 18, 2026 Jun 17, 2026
8-K Current report
Regulation FD disclosure
Jun 4, 2026 Jun 4, 2026
8-K Current report
Other events
May 21, 2026 May 21, 2026
10-Q Quarterly report May 8, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 7, 2026 May 7, 2026
ARS Annual report to shareholders Apr 27, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 27, 2026 —
DEF 14A Proxy statement Apr 27, 2026 Jun 17, 2026
S-8 Employee stock plan registration Mar 26, 2026 —
10-K Annual report Mar 26, 2026 Dec 31, 2025
8-K Current report
Results of operations, Regulation FD disclosure
Mar 26, 2026 Mar 26, 2026
8-K Current report
Other events
Mar 2, 2026 Mar 2, 2026
8-K Current report
Other events
Jan 27, 2026 Jan 27, 2026
EFFECT Filing Dec 23, 2025 —
CORRESP Letter to the SEC Dec 22, 2025 —
8-K Current report
Material agreement, Agreement ended
Dec 18, 2025 Dec 16, 2025
S-3 Shelf registration Dec 18, 2025 —
10-Q Quarterly report Nov 6, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 6, 2025 Nov 6, 2025
8-K Current report
Other events
Sep 15, 2025 Sep 15, 2025
8-K Current report
Material agreement
Aug 28, 2025 Aug 27, 2025
424B5 Prospectus supplement Aug 28, 2025 —
8-K Current report
Other events
Aug 26, 2025 Aug 26, 2025
8-K Current report
Results of operations
Aug 7, 2025 Aug 7, 2025
10-Q Quarterly report Aug 7, 2025 Jun 30, 2025
8-K Current report
Shareholder vote results
Jun 20, 2025 Jun 18, 2025
8-K Current report
Other events
Jun 3, 2025 Jun 3, 2025
8-K Current report
Other events
Jun 2, 2025 Jun 2, 2025
8-K Current report
Other events
May 8, 2025 May 8, 2025
10-Q Quarterly report May 7, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 7, 2025 May 7, 2025
ARS Annual report to shareholders Apr 28, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 28, 2025 —
DEF 14A Proxy statement Apr 28, 2025 Jun 18, 2025
424B5 Prospectus supplement Mar 20, 2025 —
S-8 Employee stock plan registration Mar 20, 2025 —
10-K Annual report Mar 20, 2025 Dec 31, 2024
8-K Current report
Results of operations
Mar 20, 2025 Mar 20, 2025
8-K Current report
Other events
Mar 12, 2025 Mar 12, 2025
8-K Current report
Other events
Feb 26, 2025 Feb 26, 2025
8-K Current report
Other events
Jan 28, 2025 Jan 28, 2025
8-K Current report
Regulation FD disclosure
Jan 13, 2025 Jan 13, 2025
8-K Current report
Other events
Dec 18, 2024 Dec 18, 2024
10-Q Quarterly report Nov 13, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 13, 2024 Nov 13, 2024
8-K Current report
Regulation FD disclosure
Oct 1, 2024 Oct 1, 2024
8-K Current report
Listing notice
Sep 13, 2024 Sep 12, 2024
8-K Current report
Regulation FD disclosure
Aug 28, 2024 Aug 28, 2024
10-Q Quarterly report Aug 8, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 8, 2024 Aug 8, 2024
8-K Current report
Other events
Jul 29, 2024 Jul 29, 2024
8-K Current report
Shareholder vote results
Jun 7, 2024 Jun 7, 2024
10-Q Quarterly report May 7, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 7, 2024 May 7, 2024
ARS Annual report to shareholders Apr 26, 2024 Dec 31, 2023
DEFA14A Additional proxy material Apr 26, 2024 —
DEF 14A Proxy statement Apr 26, 2024 Jun 7, 2024
S-8 Employee stock plan registration Mar 26, 2024 —
10-K Annual report Mar 26, 2024 Dec 31, 2023
8-K Current report
Results of operations
Mar 26, 2024 Mar 26, 2024
8-K Current report
Material agreement
Mar 13, 2024 Mar 11, 2024
424B5 Prospectus supplement Mar 13, 2024 —
8-K Current report
Results of operations
Mar 11, 2024 Mar 11, 2024
424B5 Prospectus supplement Mar 11, 2024 —
8-K Current report
Officer or director change
Feb 20, 2024 Feb 15, 2024
EFFECT Filing Jan 8, 2024 —
424B4 Prospectus Jan 8, 2024 —
8-K Current report
Other events
Jan 4, 2024 Jan 4, 2024
CORRESP Letter to the SEC Jan 4, 2024 —
UPLOAD Letter from the SEC Jan 3, 2024 —
S-3 Shelf registration Dec 29, 2023 —
10-Q Quarterly report Nov 2, 2023 Sep 30, 2023
8-K Current report
Results of operations
Nov 2, 2023 Nov 2, 2023
8-K Current report
Other events
Sep 12, 2023 Sep 12, 2023
8-K Current report
Regulation FD disclosure
Aug 24, 2023 Aug 24, 2023
10-Q Quarterly report Aug 8, 2023 Jun 30, 2023
8-K Current report
Results of operations
Aug 8, 2023 Aug 8, 2023
424B5 Prospectus supplement Jun 28, 2023 —
8-K Current report
Other events
Jun 28, 2023 Jun 28, 2023
8-K Current report
Shareholder vote results
Jun 12, 2023 Jun 9, 2023
10-Q Quarterly report May 4, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 4, 2023 May 4, 2023
8-K Current report
Officer or director change
May 1, 2023 May 1, 2023
ARS Annual report to shareholders Apr 24, 2023 Dec 31, 2022
DEFA14A Additional proxy material Apr 24, 2023 —
DEF 14A Proxy statement Apr 24, 2023 Jun 9, 2023
8-K Current report
Regulation FD disclosure
Apr 19, 2023 Apr 19, 2023
8-K Current report
Other events
Mar 28, 2023 Mar 28, 2023
424B5 Prospectus supplement Mar 27, 2023 —
S-8 Employee stock plan registration Mar 23, 2023 —
10-K Annual report Mar 23, 2023 Dec 31, 2022
8-K Current report
Results of operations
Mar 23, 2023 Mar 23, 2023
8-K Current report
Other events
Mar 15, 2023 Mar 15, 2023
8-K Current report
Regulation FD disclosure
Mar 10, 2023 Mar 10, 2023
424B5 Prospectus supplement Mar 10, 2023 —
8-K Current report
Material agreement, Results of operations
Mar 10, 2023 Mar 10, 2023
8-K Current report
Other events
Feb 22, 2023 Feb 22, 2023
8-K Current report
Other events
Feb 13, 2023 Jan 27, 2023
EFFECT Filing Jan 3, 2023 —
CORRESP Letter to the SEC Dec 29, 2022 —
UPLOAD Letter from the SEC Dec 28, 2022 —
8-K Current report
Material agreement
Dec 23, 2022 Dec 23, 2022
S-3 Shelf registration Dec 23, 2022 —
8-K Current report
Regulation FD disclosure
Nov 16, 2022 Nov 16, 2022
10-Q Quarterly report Nov 14, 2022 Sep 30, 2022
8-K Current report
Material agreement, Results of operations, Other events
Nov 14, 2022 Nov 10, 2022
424B4 Prospectus Nov 14, 2022 —
EFFECT Filing Nov 9, 2022 —
CORRESP Letter to the SEC Nov 7, 2022 —
CORRESP Letter to the SEC Nov 7, 2022 —
S-1 Registration statement Nov 7, 2022 —
UPLOAD Letter from the SEC Oct 24, 2022 —
DRS Filing Oct 20, 2022 —
8-K Current report
Regulation FD disclosure
Aug 29, 2022 Aug 29, 2022
10-Q Quarterly report Aug 9, 2022 Jun 30, 2022
8-K Current report
Results of operations
Aug 9, 2022 Aug 9, 2022
8-K Current report
Officer or director change
Jul 27, 2022 Jul 21, 2022
8-K Current report
Regulation FD disclosure
Jun 16, 2022 Jun 16, 2022
8-K Current report
Shareholder vote results
Jun 13, 2022 Jun 10, 2022
10-Q Quarterly report May 11, 2022 Mar 31, 2022
8-K Current report
Results of operations
May 11, 2022 May 11, 2022
DEFA14A Additional proxy material Apr 25, 2022 —
DEF 14A Proxy statement Apr 25, 2022 Jun 10, 2022
S-8 Employee stock plan registration Mar 30, 2022 —
10-K Annual report Mar 30, 2022 Dec 31, 2021
8-K Current report
Results of operations
Mar 30, 2022 Mar 30, 2022
8-K Current report
Regulation FD disclosure
Mar 15, 2022 Mar 15, 2022
8-K Current report
Regulation FD disclosure
Jan 10, 2022 Jan 10, 2022
8-K Current report
Results of operations
Nov 18, 2021 Nov 18, 2021
10-Q Quarterly report Nov 17, 2021 Sep 30, 2021
8-K Current report
Regulation FD disclosure
Nov 12, 2021 Nov 10, 2021
8-K Current report
Officer or director change
Nov 3, 2021 Oct 29, 2021
S-8 Employee stock plan registration Nov 2, 2021 —
8-K Current report
Bylaw or fiscal year change
Oct 14, 2021 Oct 13, 2021
424B4 Prospectus Oct 12, 2021 —
EFFECT Filing Oct 7, 2021 —
S-1MEF Filing Oct 7, 2021 —
CERT Filing Oct 7, 2021 —
8-A12B Form 8-a12b Oct 6, 2021 —
CORRESP Letter to the SEC Oct 5, 2021 —
CORRESP Letter to the SEC Oct 5, 2021 —
S-1/A Amended registration statement Oct 4, 2021 —
CORRESP Letter to the SEC Sep 10, 2021 —
S-1/A Amended registration statement Sep 10, 2021 —
UPLOAD Letter from the SEC Aug 25, 2021 —
S-1/A Amended registration statement Aug 20, 2021 —
CORRESP Letter to the SEC Jul 29, 2021 —
CORRESP Letter to the SEC Jul 29, 2021 —
S-1/A Amended registration statement Jul 29, 2021 —
UPLOAD Letter from the SEC Jul 21, 2021 —
CORRESP Letter to the SEC Jul 19, 2021 —
S-1 Registration statement Jul 19, 2021 —
UPLOAD Letter from the SEC Jul 2, 2021 —
DRSLTR Filing Jun 23, 2021 —
DRS/A Filing Jun 23, 2021 —
UPLOAD Letter from the SEC Jun 3, 2021 —
DRS Filing May 7, 2021 —
D Filing Nov 28, 2018 —
D Filing Mar 15, 2018 —
D/A Filing Jan 18, 2017 —
D Filing Nov 30, 2016 —
D Filing Mar 31, 2016 —
D/A Filing Jul 22, 2015 —
D/A Filing Apr 10, 2015 —
D Filing Apr 1, 2014 —
D/A Filing Sep 5, 2013 —
D Filing Jan 3, 2013 —
D Filing Dec 6, 2011 —
D Filing Dec 28, 2010 —
REGDEX Auto-generated paper document Jan 29, 2009 —

Showing 176 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CGTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Purchase, NY
SEC filer status
, Emerging growth company
SEC CIK
1455365
Former names
COGNITION THERAPUTICS INC (until Dec 28, 2010)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.